Are ITRM insiders buying or selling?

In the last 90 days, Iterum (ITRM) had 0 insider transactions. Track every executive trade, dollar amount, and date.

Which hedge funds own ITRM?

See every hedge fund and asset manager holding Iterum (ITRM).

How much of ITRM trades in dark pools?

Track Iterum (ITRM) dark pool activity and off-exchange block trades.

Iterum (ITRM) Smart Money — Insiders, Congress, Hedge Funds

Also trades as: ITRMF (OTC) · $vol 0M

$0.03

Last traded 2026-04-06 — delisted

NASDAQ · Healthcare · Biotechnology · $1.6M mcap · 52M float · 31.17% daily turnover · Short 53% of daily vol

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions Dark Pool Short Interest Supply Chain

Smart Money Score

No convergence signal

Key Statistics

Market Cap$1.6M

52W Range0.0271-1.42

Volume49,297,937

Avg Volume16,325,921

Beta3.01

Dividend—

Analyst Ratings

0 Buy 1 Hold 0 Sell

Consensus Hold

Company Info

CEOCorey N. Fishman

Employees9

SectorHealthcare

IndustryBiotechnology

IPO Date2018-05-25

Websiteiterumtx.com

Fitzwilliam Court
Dublin 2
IE

353 1 669 4820

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.

Latest News